MedTrace Logo

Clinical Trial to Study the Effects of Dietary Flax Beverage on Memory and Cognition

NCT04645927 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2025-06-03

No results posted yet for this study

Summary

Investigate the effects of flax beverage consumption on memory and cognition in subjects with memory deficit (i.e., amnestic MCI). In addition, it will correlate PET scan results (for a limited number of participants) and blood biomarker data with memory test results.

Conditions

  • Memory; Disturbance, Mild

Interventions

DIETARY_SUPPLEMENT

flaxseed beverage

Pizzey Ingredients Inc. introduced a flax beverage product that is a plant-based beverage product that is designed as an alternative to non-diary "milks" (almond milk \& soy milk). Each 330 ml serving of flax beverage contains 15 g flaxseed, which amounts to 3.75 gm of omega-3 fatty acid. Preventing MCI or even AD may be within reach, if appropriate measures are taken early enough using strategies such as dietary supplementation.

DIETARY_SUPPLEMENT

control beverage

Oat fibre control. For 180 days (6 months) participants will consume 2 servings of 330 ml of placebo beverage (i.e. normal fiber beverage; control) per day.

Sponsors & Collaborators

  • Pizzey Ingredients

    collaborator UNKNOWN

  • Canadian Agricultural Partnership

    collaborator UNKNOWN

  • St. Boniface Hospital

    lead OTHER

Principal Investigators

  • Barry Campbell, MD · St. Boniface Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-09
Primary Completion
2023-09-21
Completion
2023-12-19

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04645927 on ClinicalTrials.gov